Phase II study of panitumumab with FOLFOX or FOLFIRI as 1st line treatment in patients with metastatic colorectal cancer in Japan

ABSTRACT: Interventions: The investigators choose the treatment A or Barbitrarily. A: FOLFOX + panitumumab B: FOLFIRI + panitumumab Repeat every 14 days until meeting the withdrawal criteria. Primary outcome(s): Overall response rate (ORR) Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2620434 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR